Of note, the CRG signature exhibited better response prediction capacity for BC patients with wild-type FGFR3, of whom those with lower CRG score might be more sensitive to the immunotherapeutic treatment with anti-PD-1 or anti-PD-L1 drugs. Here, FGFR3 is linked to breast cancer.